Skip to main content
. 2017 Feb 21;11:364–370. doi: 10.1016/j.dib.2017.02.040

Table 1.

Usage and source of various cohorts in this work.

Cohort Name Used in this study in: Numbers of individuals Original Reference
Sydney PCR cohort Figures 2, 3, 4, 5, 6, 7, 9 n=39 untreated MS
n=40 healthy controls
[1]
Miami cohort Figures 3, 6, 7 n=73 untreated MS
n=32 healthy controls
[1]
Treated MS cohort Figure 10 Total, n=78:
n=10, glatiramer acetate
n=18, fingolimod
n=20, interferon beta
n=23, natalizumab
n=7, dimethyl fumarate
[8]
ANZgene (microarray) cohort Figures 1B, 6, 7 n=99 untreated MS;
n=45 healthy controls
[2]
Sydney RNASeq cohort Figures 1, 3, 6, 7, Supplementary Figure. 1 and 2 n=32 untreated MS;
n=40 healthy controls
[4]
CIS cohort Figure 1B n=42 CIS [3]